Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B7-H3 antibody-drug conjugate
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intraperitoneal
01
Overview
This B7-H3 antibody-drug conjugate (ADC) is an investigational therapeutic consisting of a monoclonal antibody targeting the CD276 (B7-H3) antigen, conjugated to the DNA-alkylating payload tesirine (SG3249). Developed by the ORBIT platform at MD Anderson Cancer Center, the agent is designed to treat B7-H3-expressing malignancies, with a particular focus on primary and metastatic osteosarcoma. B7-H3 is a transmembrane protein often overexpressed in pediatric and adult solid tumors while maintaining low expression in normal tissues, providing a wide therapeutic window. The tesirine payload is a pyrrolobenzodiazepine (PBD) dimer that induces sequence-specific DNA cross-linking, leading to cell cycle arrest and apoptosis. Preclinical data presented at AACR 2026 demonstrated potent cytotoxicity in patient-derived xenograft (PDX) models and significant efficacy in preventing and treating pulmonary metastases in osteosarcoma models.
- Other names
- B7-H3-targeting antibody-drug conjugateB-7-H3-targeting antibody-drug conjugateB 7-H3-targeting antibody-drug conjugate
02
Targets
B7-H3
Beyond the preview
Go deeper on B7-H3 antibody-drug conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B7-H3 antibody-drug conjugate.